moving my dose day by a day or two never did anything noticeable for me
#semaglutide 2024-12-25
Wednesday43 messages8 participantstimes are UTC
Highlights from this day
give it four weeks
did anybody find a difference between SGN and pharmacy at the same 2.5
slower worked better
went too fast once
STEP is several trials, so saying STEP said x is usually wrong without a number after it
how long till steady state, ive read the half life is about a week
the plateau hit me at 27 weeks and moved again about a month later without a dose change, we shall see
steady state is the bit people skip, judging a new dose after eight days tells you almost nothing
unrelated but £185 a month for compounded against what brand costs locally is why most people here use vials, still working it out
compounded and brand felt the same to me at 2.4, which is one person and nothing more
my 40 vial in 3ml gives 4mg/ml so 0.5 lands on 12 units, thats why i picked that volume
FLOW was the kidney outcomes trial and it gets quoted in here for things it didnt measure
changed my mind on the four week rule, i think it depends entirely on how the current dose feels, happy to be corrected
my PeptideMeter report on the QSC vial came back 99.4 against a certificate saying 97.4
brand vs compounded, is there a difference people can actually feel
my plateau was the scale stopping while appetite stayed suppressed, which is a different problem
SELECT is the one people bring up when they want to argue this is a heart drug now
the headline is a roughly 20% relative reduction in the three point MACE composite
hazard ratio came in around 0.80 with a confidence interval that stayed under 1
20% sounds enormous
relative. absolute difference was a couple of percentage points over several years
both numbers are true and they feel completely different, which is the whole problem with reporting this stuff
this is the single most misquoted result of the last few years
📊8
it mattered here for a different reason. it changed what my GP was willing to talk about
before SELECT it was a cosmetic conversation. after, it was a risk conversation
did the benefit track with how much weight people lost
the separation in the event curves started earlier than the weight loss could plausibly explain, which is why people argue for a direct vascular effect
argue is the right word though. its an inference from curve shape, not a proven mechanism
so is it the weight or the drug
probably both and SELECT was not designed to separate them
worth noting the entry criteria. established cardiovascular disease and BMI 27 or over, no diabetes
if you are 34 with no history you are not in that population and the hazard ratio is not yours
thats the part i keep having to explain to people
✅5
also see #bloodwork, a few of us have long lipid series that got a lot less interesting than we expected
less interesting how
my LDL barely moved. weight went down 19kg and LDL did almost nothing. it happens
yep, and CRP often moves more than the lipids do. different levers
brb
nhs_pathway_nellit mattered here for a different reason. it changed what my GP was willing to talk about
the GP thing you said — did they actually change anything or just talk differently
talked differently for about a year and then referred me. so, eventually
back. anyway my takeaway is SELECT is good news that doesnt tell me what to do this week
correct, and thats most trials
🎯7